Tag Archives: CART

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. They

Yesterday Celgene finalized its acquisition of Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. With only a few hundred patients ever treated with their therapies, $20B represents a lot of promise in

This post was written by Jason Gardner, Atlas EIR and CEO of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC. A new type of medicine was approved in Europe at the end of May that culminated